A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease.
A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease.
复制标题
DOI：
10.1002/dad2.12128
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Knapskog AB
中科院分区：
文献类型：
--
作者：
Edwin TH;Henjum K;Nilsson LNG;Watne LO;Persson K;Eldholm RS;Saltvedt I;Halaas NB;Selbæk G;Engedal K;Strand BH;Knapskog AB
阿尔茨海默病(AD)的进展速度各不相同，可能受到髓系细胞上表达的受体(TREM2)活性的影响。我们探讨了脑脊液(CSF)中可溶性TREM2(STREM2)是否与临床进展率有关。临床AD患者(N=6231)在确诊后进行了长达3年的随访。对认知健康对照组(N=442)进行为期5年的随访。采用酶联免疫吸附试验检测脑脊液中sTREM2的含量。基于组的轨迹建模显示了不同的临床进展组。脑脊液sTREM2升高与临床进展缓慢相关。缓慢和中等进展组的脑脊液sTREM2高于认知健康组，后者的水平与临床进展快的患者相似。脑脊液sTREM2水平与AD的临床进展相关，与核心生物标志物无关。这可能有助于评估与患者护理和临床试验招募相关的疾病发展。
The progression rate of Alzheimer's disease (AD) varies and might be affected by the triggering receptor expressed on myeloid cells (TREM2) activity. We explored if cerebrospinal fluid (CSF) soluble TREM2 (sTREM2), a proxy of microglial activity, is associated with clinical progression rate. Patients with clinical AD (N = 231) were followed for up to 3 years after diagnosis. Cognitively healthy controls (N = 42) were followed for 5 years. CSF sTREM2 was analyzed by enzyme‐linked immunosorbent assay. Group‐based trajectory modeling revealed distinct clinical progression groups. Higher CSF sTREM2 was associated with slow clinical progression. The slow‐ and medium‐progressing groups had higher CSF sTREM2 than the cognitively healthy, who had a similar level to patients with rapid clinical progression. CSF sTREM2 levels were associated with clinical progression in AD, regardless of core biomarkers. This could be useful in assessing disease development in relation to patient care and clinical trial recruitment.